News

In people with newly diagnosed multiple myeloma following a stem cell transplant, a triple-combination maintenance therapy — of Revlimid (lenalidomide), Kyprolis (carfilzomib) and dexamethasone — significantly extended the time to disease progression or death, by 49%, compared with Revlimid alone. That’s according to an interim analysis of…

Janssen Pharmaceuticals is seeking European Union approval for talquetamab, a subcutaneous (under-the-skin) antibody therapy for hard-to-treat multiple myeloma. The request, in the form of a marketing authorization application to the European Medicines Agency (EMA), will be reviewed under accelerated assessment, which reduces the expected review period from…

Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) asking that talquetamab be approved to treat relapsed or refractory multiple myeloma. “We look forward to working closely with the FDA in their review of the talquetamab submission,” Peter Lebowitz, MD, PhD, global oncology…

The International Myeloma Foundation (IMF) is one of the nonprofit organizations awarded the 2022 Amazon Web Services (AWS) IMAGINE Grant, which was established to help harness technology for patients’ needs. IMF was a winner in the Momentum to Modernize category, wherein its efforts to use cloud technology to educate…

SP-3164, an investigational small molecule protein degrader, showed potential for improved anti-multiple myeloma activity over similar approved compounds. That’s according to preclinical data from its developer Salarius Pharmaceuticals that showed SP-3164 triggered the death of lab-grown cancer cells and held back cancer growth in a mouse model of…

Caribou Biosciences will soon start testing its new CAR T-cell therapy candidate, CB-011, in people with relapsed or refractory multiple myeloma. A Phase 1 trial will begin enrolling eligible adults in early 2023 at multiple centers, according to the company. The announcement follows clearance of the company’s investigational…

GC012F, Gracell Biotechnologies’ investigational dual FastCAR T-cell therapy, was safe and highly effective at eradicating cancer cells in people with high-risk, newly diagnosed multiple myeloma, according to preliminary findings from an ongoing Phase 1 trial. “We are thrilled to report that BCMA/CD19 dual targeting FasTCAR-T GC012F is showing…

The U.S. Food and Drug Administration (FDA) will review BioLineRx’s application to approve Aphexda, formerly known as motixafortide, as an add-on stem cell mobilization therapy to improve stem cell transplants in people with multiple myeloma. The decision comes about two months after the company submitted a…

The efficacy and safety of Blenrep (belantamab mafodotin) as a treatment for relapsed/refractory multiple myeloma (RRMM) in a real-world setting is similar to what has been reported in clinical trials, according to a study from Israel. “Response rate, duration of response and toxicity profile appear to be comparable to…

Janssen’s Tecvayli (teclistamab) has been approved for certain adults with relapsed or refractory multiple myeloma in the U.S., but access is limited due to potential side effects. In particular, the approval by the U.S. Food and Drug Administration (FDA) is for patients who have received at least four…